PMC:7228307 / 25437-25758 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"446","span":{"begin":170,"end":177},"obj":"Gene"},{"id":"447","span":{"begin":200,"end":207},"obj":"Gene"},{"id":"448","span":{"begin":212,"end":217},"obj":"Gene"},{"id":"450","span":{"begin":68,"end":76},"obj":"Species"}],"attributes":[{"id":"A446","pred":"tao:has_database_id","subj":"446","obj":"Gene:2214"},{"id":"A447","pred":"tao:has_database_id","subj":"447","obj":"Gene:2212"},{"id":"A448","pred":"tao:has_database_id","subj":"448","obj":"Gene:2214"},{"id":"A450","pred":"tao:has_database_id","subj":"450","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"otoxic anticancer therapeutic mAbs depend on these for their MOA in patients is unclear. The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects o"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T255","span":{"begin":251,"end":255},"obj":"Body_part"}],"attributes":[{"id":"A255","pred":"fma_id","subj":"T255","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"otoxic anticancer therapeutic mAbs depend on these for their MOA in patients is unclear. The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects o"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T49","span":{"begin":61,"end":64},"obj":"Disease"}],"attributes":[{"id":"A49","pred":"mondo_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/MONDO_0016702"}],"text":"otoxic anticancer therapeutic mAbs depend on these for their MOA in patients is unclear. The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects o"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T486","span":{"begin":170,"end":172},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T487","span":{"begin":200,"end":202},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T488","span":{"begin":212,"end":214},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T489","span":{"begin":251,"end":255},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"otoxic anticancer therapeutic mAbs depend on these for their MOA in patients is unclear. The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects o"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T132","span":{"begin":215,"end":217},"obj":"Chemical"}],"attributes":[{"id":"A132","pred":"chebi_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/CHEBI_73814"},{"id":"A133","pred":"chebi_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/CHEBI_8753"}],"text":"otoxic anticancer therapeutic mAbs depend on these for their MOA in patients is unclear. The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects o"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T151","span":{"begin":251,"end":255},"obj":"http://purl.obolibrary.org/obo/CL_0000000"}],"text":"otoxic anticancer therapeutic mAbs depend on these for their MOA in patients is unclear. The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects o"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"446","span":{"begin":170,"end":177},"obj":"Gene"},{"id":"447","span":{"begin":200,"end":207},"obj":"Gene"},{"id":"448","span":{"begin":212,"end":217},"obj":"Gene"},{"id":"450","span":{"begin":68,"end":76},"obj":"Species"}],"attributes":[{"id":"A450","pred":"pubann:denotes","subj":"450","obj":"Tax:9606"},{"id":"A446","pred":"pubann:denotes","subj":"446","obj":"Gene:2214"},{"id":"A448","pred":"pubann:denotes","subj":"448","obj":"Gene:2214"},{"id":"A447","pred":"pubann:denotes","subj":"447","obj":"Gene:2212"}],"text":"otoxic anticancer therapeutic mAbs depend on these for their MOA in patients is unclear. The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects o"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T254","span":{"begin":251,"end":255},"obj":"Body_part"}],"attributes":[{"id":"A254","pred":"fma_id","subj":"T254","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"otoxic anticancer therapeutic mAbs depend on these for their MOA in patients is unclear. The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects o"}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T67","span":{"begin":251,"end":263},"obj":"http://purl.obolibrary.org/obo/GO_0001906"}],"text":"otoxic anticancer therapeutic mAbs depend on these for their MOA in patients is unclear. The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects o"}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T67","span":{"begin":251,"end":263},"obj":"http://purl.obolibrary.org/obo/GO_0001906"}],"text":"otoxic anticancer therapeutic mAbs depend on these for their MOA in patients is unclear. The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects o"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T67","span":{"begin":251,"end":263},"obj":"http://purl.obolibrary.org/obo/GO_0001906"}],"text":"otoxic anticancer therapeutic mAbs depend on these for their MOA in patients is unclear. The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects o"}